【摘要】 近年来，随着对炎症性肠病(IBD)的深入研究，各种生物制剂不断涌现，IBD治疗进入新时代。乌司奴单抗是一种抗白介素(IL)-12/23的新型生物制剂，为传统药物治疗或抗肿瘤坏死因子α(TNF-α)治疗失败的克罗恩病(CD)患者提供了新选择。本文就乌司奴单抗治疗CD的作用机制、临床疗效、安全性、失应答及治疗调整做一综述，发现乌司奴单抗具有起效快、疗效显著和安全性高的优势，但目前其仍存在着临床应用时间短、临床经验不足等问题。未来需要更多临床研究及随访数据支持。更多还原

【Abstract】 As the study of inflammatory bowel disease (IBD)advances，various biological agents for IBD are emerging，ushering in a new area of IBD treatment.Ustekinumab，an anti-interleukin-12/23 agent，is a new option for Crohn’s disease patients with prior failure of traditional pharmacological treatment or tumor necrosis factor-alpha antagonist (TNF-α).We reviewed the mechanisms of action，clinical effectiveness，safety，loss of response and the adjustment of therapy regarding ustekinumab in Crohn’s disease，and summarized the strengths of ustekinumab treatment，such as rapid onset，significant efficacy and high safety.However，this treatment needs to be further examined by clinical and follow-up studies since it has been used for a short period of time with insufficient clinical evidence.更多还原